Buzzing Politics
  • News
  • Privacy Policy
  • Terms of Use
  • Disclaimer
Select Page

AI Disruption Is Reshaping Software — And Credit Markets May Be Next

by Piero Cingari | Feb 23, 2026 | General

As investors debate whether software stocks have bottomed and the Nasdaq can regain momentum, some market watchers warn the AI boom may not play out as Wall Street expects. For Jordi Visser, head of AI Macro Nexus Research at 22V Research, the real story isn’t...
Brighthouse Financial Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Brighthouse Financial Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

by Avi Kapoor | Feb 23, 2026 | General

Brighthouse Financial, Inc. (NASDAQ:BHF) will release earnings results for its fourth quarter during the week of Feb. 23. Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $5.19 per share, up from $5.07 per share in the...

Dog And Cat Food Maker Freshpet Issues Cautious Outlook

by Akanksha Bakshi | Feb 23, 2026 | General

Freshpet Inc. (NASDAQ:FRPT) stock slipped in early trading Monday after the pet food maker delivered a fourth-quarter earnings beat but posted revenue that came in just shy of Wall Street expectations. Net sales increased 8.6% to $285.2 million from $262.7 million a...

Tom Lee: Bitcoin’s 50% Drop Is A ‘Crypto Squall,’ Not A Winter

by Parshwa Turakhiya | Feb 23, 2026 | General

Fundstrat’s Tom Lee called Bitcoin’s (CRYPTO: BTC) 50% drawdown a “crypto squall” rather than a structural collapse, arguing technology and crypto sectors could revive as tariff uncertainty lifts. The Squall vs. Winter Thesis Lee told CNBC on Friday that Bitcoin’s...

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

by Vandana Singh | Feb 23, 2026 | General

MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday’s premarket session following the announcement of positive topline results from its Phase 2 clinical trial of sonelokimab in treating axial spondyloarthritis. Axial Spondyloarthritis is a chronic,...
« Older Entries
Next Entries »

Recent Posts

  • What’s Going On With Shopify Stock Monday?
  • Trump Proposes Gaza Stablecoin As Critics Warn It Could ‘Separate Economy From West Bank’
  • P/E Ratio Insights for Hims & Hers Health
  • Michael Saylor Hits 100 Bitcoin Buys—And He’s Not Stopping Despite A $7 Billion Loss
  • General Mills Outlook Clouded By Soft Consumer Spending, Pet Segment Struggles, Analysts Say

Recent Comments

    Archives

    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019

    Categories

    • Breaking
    • Business
    • Daily
    • General
    • Markets
    • News
    • Reports
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • News
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    Copyright 2019 Karmaholic Media LLC. All Rights Reserved.